Publication: 3640

Publication: 3640

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Vascular Thrombotic Events (VTEs) in the GRIFFIN Study (AFT-29)

URL

Google Scholar

Citation:: Clin Lymphoma Myeloma Leuk vol 21 (suppl 2) abstr P-180

Meeting Instance:: IMW 2021
Year:: 2021
Type:: Abstract
Sub type:
Funding:: AFT
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3902

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen Research & Development
Grants:

Corr. Author:
Authors:: Douglas W. Sborov Muhamed Baljevic Brandi Reeves Jacob Laubach Yvonne A. Efebera Cesar Rodriguez Luciano J. Costa Ajai Chari Rebecca Silbermann Sarah A. Holstein Larry D. Jr. Anderson Jonathan L. Kaufman Nina Shah Huiling Pei Sharmila Patel Annelore Cortoos Blake Bartlett Jessica Vermeulen Thomas S. Lin Peter M. Voorhees Paul G. Richardson

Networks:: CA824, LAPS-AL002, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-UT003, NC002, NE003, NY021, OH008, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: